Valuation: Atossa Therapeutics, Inc.

Market Cap 24.45M 21.7M 20.31M 18.41M 34.77M 2.36B 35.02M 244M 94.88M 1.2B 91.77M 89.8M 3.87B P/E 2026 *
-0.65x
P/E 2027 * -0.88x
Enterprise Value 24.45M 21.7M 20.31M 18.41M 34.77M 2.36B 35.02M 244M 94.88M 1.2B 91.77M 89.8M 3.87B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 week+23.12%
Current month+25.64%
1 month-2.78%
3 months+7.46%
6 months-52.43%
Current year-72.32%
1 week 1.96
Extreme 1.96
2.54
1 month 1.82
Extreme 1.82
2.61
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
49.95
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26 A
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 A Free

Director

10,000 0.1161%
5/12/26 A Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+23.12%-83.67%-77.46% 24.45M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average +0.39%+1.61%+39.15%+105.44% 39.36B
Weighted average by Cap. +0.77%-0.94%+56.82%+134.45%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.33M -29.32M -26.58M -50.19M -3.4B -50.55M -352M -137M -1.74B -132M -130M -5.58B -38.03M -33.76M -31.59M -28.63M -54.07M -3.67B -54.46M -379M -148M -1.87B -143M -140M -6.01B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
06/10/26 $2.450 0.00% 54,625
05/10/26 $2.450 +4.70% 53,315
02/10/26 $2.340 +3.08% 74,271
01/10/26 $2.270 +16.41% 113,600
30/09/26 $1.950 -2.01% 67,768
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.450USD
Average target price
19.00USD
Spread / Average Target
+675.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock